This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dehoux, M. Articles by Thissen, J.-P. Search for Related Content PubMed PubMed Citation Articles by Dehoux, M. Articles by Thissen, J.-P.

Role of the Insulin-Like Growth Factor I Decline in the Induction of Atrogin-1/MAFbx during Fasting and Diabetes

Unite de Diabetologie et Nutrition, Universite Catholique de Louvain (M.D., R.V.B., N.P., P.L., J.V., J.-M.K., J.-P.T.), B-1200 Brussels, Belgium; and Department of Pediatrics, University of North Carolina (L.U.), Chapel Hill, North Carolina 27599-7039

Address all correspondence and requests for reprints to: Dr. Jean-Paul Thissen, Unite de Diabetologie et Nutrition, Universite Catholique de Louvain, 54 avenue Hippocrate, B-1200 Brussels, Belgium. E-mail: thissen{at}diab.ucl.ac.be.

In catabolic conditions, atrogin-1/MAFbx, a muscle-specific ubiquitin-ligase required for muscle atrophy, is increased, and concentrations of IGF-I, a growth factor known to have antiproteolytic action, are reduced. To define the relationship between the decline in IGF-I and the induction of atrogin-1/MAFbx, we studied the effect of IGF-I replacement on atrogin-1/MAFbx mRNA in rats fasted for 51 h and in rats made diabetic with streptozotocin (STZ). Fasting produced a 5.8-fold increase in atrogin-1/MAFbx (P < 0.001). This was attenuated to a 2.5-fold increase by injections of IGF-I (P < 0.05 vs. fasting). Animals with STZ-induced diabetes experienced a 15.1-fold increase in atrogin-1/MAFbx (P < 0.001). Normalization of their circulating IGF-I concentrations by IGF-I infusion blunted the induction of atrogin-1/MAFbx to 6.3-fold (P < 0.05 vs. STZ diabetes without IGF-I). To further delineate the regulation of atrogin-1/MAFbx by IGF-I, we studied a model of cultured muscle cells. We observed that IGF-I produced a time- and dose-dependent reduction of atrogin-1/MAFbx mRNA, with a 50% effective dose of 5 nM IGF-I, a physiological concentration. The degradation rate of atrogin-1/MAFbx mRNA was not affected by IGF-I, suggesting that the reduction of atrogin-1/MAFbx mRNA by IGF-I is a transcriptional effect. Exposure of muscle cells in culture to dexamethasone increased atrogin-1/MAFbx mRNA with a 50% effective dose of 10 nM, a pharmacological concentration. In the presence of dexamethasone, IGF-I at physiological concentrations retained its full inhibitory effect on atrogin-1/MAFbx mRNA. We conclude that IGF-I inhibits atrogin-1/MAFbx expression and speculate that this effect might contribute to the antiproteolytic action of IGF-I in muscle.

This article has been cited by other articles:

				V. C. Foletta, M. J. Prior, N. Stupka, K. Carey, D. H. Segal, S. Jones, C. Swinton, S. Martin, D. Cameron-Smith, and K. R. Walder NDRG2, a novel regulator of myoblast proliferation, is regulated by anabolic and catabolic factors J. Physiol., April 1, 2009; 587(7): 1619 - 1634. [Abstract] [Full Text] [PDF]

				O. Schakman, S. Kalista, L. Bertrand, P. Lause, J. Verniers, J. M. Ketelslegers, and J. P. Thissen Role of Akt/GSK-3{beta}/{beta}-Catenin Transduction Pathway in the Muscle Anti-Atrophy Action of Insulin-Like Growth Factor-I in Glucocorticoid-Treated Rats Endocrinology, August 1, 2008; 149(8): 3900 - 3908. [Abstract] [Full Text] [PDF]

				T. C. Vary, R. A. Frost, and C. H. Lang Acute alcohol intoxication increases atrogin-1 and MuRF1 mRNA without increasing proteolysis in skeletal muscle Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2008; 294(6): R1777 - R1789. [Abstract] [Full Text] [PDF]

				O Schakman, H Gilson, and J P Thissen Mechanisms of glucocorticoid-induced myopathy J. Endocrinol., April 1, 2008; 197(1): 1 - 10. [Abstract] [Full Text] [PDF]

				A I Martin, E Castillero, M Granado, M Lopez-Menduina, M A Villanua, and A Lopez-Calderon Adipose tissue loss in adjuvant arthritis is associated with a decrease in lipogenesis, but not with an increase in lipolysis J. Endocrinol., April 1, 2008; 197(1): 111 - 119. [Abstract] [Full Text] [PDF]

				L. S. Quinn, B. G. Anderson, and S. R. Plymate Muscle-specific overexpression of the type 1 IGF receptor results in myoblast-independent muscle hypertrophy via PI3K, and not calcineurin, signaling Am J Physiol Endocrinol Metab, December 1, 2007; 293(6): E1538 - E1551. [Abstract] [Full Text] [PDF]

				R. A. Frost and C. H. Lang Protein kinase B/Akt: a nexus of growth factor and cytokine signaling in determining muscle mass J Appl Physiol, July 1, 2007; 103(1): 378 - 387. [Abstract] [Full Text] [PDF]

				M. Granado, A. I Martin, M{a} A. Villanua, and A. Lopez-Calderon Experimental arthritis inhibits the insulin-like growth factor-I axis and induces muscle wasting through cyclooxygenase-2 activation Am J Physiol Endocrinol Metab, June 1, 2007; 292(6): E1656 - E1665. [Abstract] [Full Text] [PDF]

				M. Dehoux, C. Gobier, P. Lause, L. Bertrand, J.-M. Ketelslegers, and J.-P. Thissen IGF-I does not prevent myotube atrophy caused by proinflammatory cytokines despite activation of Akt/Foxo and GSK-3beta pathways and inhibition of atrogin-1 mRNA Am J Physiol Endocrinol Metab, January 1, 2007; 292(1): E145 - E150. [Abstract] [Full Text] [PDF]

				A. R. Judge, A. Koncarevic, R. B. Hunter, H.-C. Liou, R. W. Jackman, and S. C. Kandarian Role for I{kappa}B{alpha}, but not c-Rel, in skeletal muscle atrophy Am J Physiol Cell Physiol, January 1, 2007; 292(1): C372 - C382. [Abstract] [Full Text] [PDF]

				M Granado, A I Martin, T Priego, A Lopez-Calderon, and M A Villanua Tumour necrosis factor blockade did not prevent the increase of muscular muscle RING finger-1 and muscle atrophy F-box in arthritic rats. J. Endocrinol., October 1, 2006; 191(1): 319 - 326. [Abstract] [Full Text] [PDF]

				P. Costelli, M. Muscaritoli, M. Bossola, F. Penna, P. Reffo, A. Bonetto, S. Busquets, G. Bonelli, F. J. Lopez-Soriano, G. B. Doglietto, et al. IGF-1 is downregulated in experimental cancer cachexia Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2006; 291(3): R674 - R683. [Abstract] [Full Text] [PDF]

				V. G. Coffey, A. Shield, B. J. Canny, K. A. Carey, D. Cameron-Smith, and J. A. Hawley Interaction of contractile activity and training history on mRNA abundance in skeletal muscle from trained athletes Am J Physiol Endocrinol Metab, May 1, 2006; 290(5): E849 - E855. [Abstract] [Full Text] [PDF]

				W. A. Bauman, S. C. Kirshblum, N. G. Morrison, C. M. Cirnigliaro, R.-L. Zhang, and A. M. Spungen Effect of Low-Dose Baclofen Administration on Plasma Insulin-like Growth Factor-I in Persons With Spinal Cord Injury. J. Clin. Pharmacol., April 1, 2006; 46(4): 476 - 482. [Abstract] [Full Text] [PDF]

				K. R. Sultan, B. Henkel, M. Terlou, and H. P. Haagsman Quantification of hormone-induced atrophy of large myotubes from C2C12 and L6 cells: atrophy-inducible and atrophy-resistant C2C12 myotubes Am J Physiol Cell Physiol, February 1, 2006; 290(2): C650 - C659. [Abstract] [Full Text] [PDF]

				M. Granado, T. Priego, A. I. Martin, M{a} A. Villanua, and A. Lopez-Calderon Ghrelin receptor agonist GHRP-2 prevents arthritis-induced increase in E3 ubiquitin-ligating enzymes MuRF1 and MAFbx gene expression in skeletal muscle Am J Physiol Endocrinol Metab, December 1, 2005; 289(6): E1007 - E1014. [Abstract] [Full Text] [PDF]

				O. Schakman, H. Gilson, V. de Coninck, P. Lause, J. Verniers, X. Havaux, J. M. Ketelslegers, and J. P. Thissen Insulin-Like Growth Factor-I Gene Transfer by Electroporation Prevents Skeletal Muscle Atrophy in Glucocorticoid-Treated Rats Endocrinology, April 1, 2005; 146(4): 1789 - 1797. [Abstract] [Full Text] [PDF]

				M. F. C. Heszele and S. R. Price Insulin-Like Growth Factor I: The Yin and Yang of Muscle Atrophy Endocrinology, November 1, 2004; 145(11): 4803 - 4805. [Full Text] [PDF]